BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15891884)

  • 1. Development of a whole cell vaccine for acute myeloid leukaemia.
    Cheuk AT; Chan L; Czepulkowski B; Berger SA; Yagita H; Okumura K; Farzaneh F; Mufti GJ; Guinn BA
    Cancer Immunol Immunother; 2006 Jan; 55(1):68-75. PubMed ID: 15891884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
    Cheuk AT; Guinn BA
    Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
    Chan L; Hardwick NR; Guinn BA; Darling D; Gäken J; Galea-Lauri J; Ho AY; Mufti GJ; Farzaneh F
    Cancer Immunol Immunother; 2006 Aug; 55(8):1017-24. PubMed ID: 16450142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].
    Mohty M; Gaugler B; Calmels B; Blaise D; Vey N; Chabannon C; Olive D
    Bull Cancer; 2003; 90(8-9):751-7. PubMed ID: 14609765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
    Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
    Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.
    Guinn BA; Gilkes AF; Woodward E; Westwood NB; Mufti GJ; Linch D; Burnett AK; Mills KI
    Biochem Biophys Res Commun; 2005 Aug; 333(3):703-13. PubMed ID: 15963951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Rafelson WM; Reagan JL; Fast LD; Lim SH
    Leuk Lymphoma; 2017 Nov; 58(11):2523-2531. PubMed ID: 28351186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of myeloid leukaemia.
    Guinn BA; Mohamedali A; Thomas NS; Mills KI
    Cancer Immunol Immunother; 2007 Jul; 56(7):943-57. PubMed ID: 17180671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.
    van Luijn MM; van den Ancker W; Chamuleau ME; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Immunotherapy; 2010 Jan; 2(1):85-97. PubMed ID: 20635891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of acute myeloid leukemia: current approaches.
    Smits EL; Berneman ZN; Van Tendeloo VF
    Oncologist; 2009 Mar; 14(3):240-52. PubMed ID: 19289488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Immunobiology; 2006; 211(6-8):677-85. PubMed ID: 16920506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological weapons against acute myeloid leukaemia.
    Galea-Lauri J
    Immunology; 2002 Sep; 107(1):20-7. PubMed ID: 12225359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in leukaemia.
    Van De Velde AL; Anguille S; Berneman ZN
    Acta Clin Belg; 2012; 67(6):399-402. PubMed ID: 23340144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.
    Westers TM; Stam AG; Scheper RJ; Regelink JC; Nieuwint AW; Schuurhuis GJ; van de Loosdrecht AA; Ossenkoppele GJ
    Cancer Immunol Immunother; 2003 Jan; 52(1):17-27. PubMed ID: 12536236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.
    Kaleka G; Schiller G
    Leuk Res; 2022 Jan; 112():106732. PubMed ID: 34864447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods.
    Stripecke R; Levine AM; Pullarkat V; Cardoso AA
    Leukemia; 2002 Oct; 16(10):1974-83. PubMed ID: 12357348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.
    Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Biomed Pharmacother; 2007 Jul; 61(6):306-14. PubMed ID: 17368821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.
    Burnett AK; Goldstone AH; Stevens RM; Hann IM; Rees JK; Gray RG; Wheatley K
    Lancet; 1998 Mar; 351(9104):700-8. PubMed ID: 9504514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.